Education
About Us
Working with TipRanks
Follow Us
BioArctic AB Class B (DE:B9A)
FRANKFURT:B9A
B9A Stock Chart & Stats
€28.52
-€0.37(-2.00%)
At close: 4:00 PM EST
€28.52
-€0.37(-2.00%)
Day’s Range― - ―
52-Week Range€14.19 - €34.96
Previous CloseN/A
Volume0.00
Average Volume (3M)292.00
Market Cap
€2.64B
Enterprise Value€27.18B
Total Cash (Recent Filing)€2.19B
Total Debt (Recent Filing)€72.42M
Price to Earnings (P/E)26.9
Beta0.53
Next Earnings
May 20, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding74,241,486
10 Day Avg. Volume102
30 Day Avg. Volume292
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)13.99
Price to Sales (P/S)13.76
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)€112.00M
Bulls Say, Bears Say
Bulls Say
Profitability RecoveryA material profitability inflection in 2025 with very high gross and net margins improves internal cash-generation potential and earnings quality. Sustained higher margins increase reinvestment capacity for R&D or partnering and materially raises resilience versus prior loss years if maintained.
Conservative Balance SheetVery low leverage provides financial flexibility to fund clinical programs, absorb milestone timing variability, and access capital on better terms. A conservative balance sheet reduces refinancing risk during biotech cycles and supports sustained investment in development over the next several quarters.
Partnering-led Business ModelA licensing and partnership model with major pharma shifts commercialization risk away from the company, generating upfront, milestone and royalty-linked cash streams. Strong partner ties can deliver durable non-dilutive funding and accelerate late-stage development without full commercialization overhead.
Bears Say
Free Cash Flow WeaknessZero free cash flow in 2025, despite operating cash rebound, suggests heavy reinvestment or payouts to partners and limits internal funding flexibility. Over the medium term this raises reliance on partner payments or financing to cover development spend and support growth initiatives.
Revenue/Earnings Concentration On MilestonesLarge swings tied to milestone recognition make topline and earnings less predictable. Durable revenue depends on partner progress and commercial execution outside BioArctic's direct control, increasing the probability of episodic earnings and complicating multi-quarter cash and planning forecasts.
Historic Profitability Volatility & Debt TrendPrior multi-year swings between losses and profits, combined with a rise in absolute debt, create downside risk if profitability reverses. Even with low leverage today, renewed losses could pressure equity, constrain R&D funding, and force dilutive or costly financing decisions over the medium term.
BioArctic AB Class B News
B9A FAQ
What was BioArctic AB Class B’s price range in the past 12 months?
BioArctic AB Class B lowest stock price was €14.19 and its highest was €34.96 in the past 12 months.
What is BioArctic AB Class B’s market cap?
BioArctic AB Class B’s market cap is €2.64B.
When is BioArctic AB Class B’s upcoming earnings report date?
BioArctic AB Class B’s upcoming earnings report date is May 20, 2026 which is in 69 days.
How were BioArctic AB Class B’s earnings last quarter?
BioArctic AB Class B released its earnings results on Feb 18, 2026. The company reported -€0.009 earnings per share for the quarter, beating the consensus estimate of -€0.051 by €0.041.
Is BioArctic AB Class B overvalued?
According to Wall Street analysts BioArctic AB Class B’s price is currently Overvalued.
Does BioArctic AB Class B pay dividends?
BioArctic AB Class B does not currently pay dividends.
What is BioArctic AB Class B’s EPS estimate?
BioArctic AB Class B’s EPS estimate is -0.03.
How many shares outstanding does BioArctic AB Class B have?
BioArctic AB Class B has 74,241,486 shares outstanding.
What happened to BioArctic AB Class B’s price movement after its last earnings report?
BioArctic AB Class B reported an EPS of -€0.009 in its last earnings report, beating expectations of -€0.051. Following the earnings report the stock price went up 18.188%.
Which hedge fund is a major shareholder of BioArctic AB Class B?
Currently, no hedge funds are holding shares in DE:B9A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioArctic AB Class B
BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---